Explaining the upcoming interim analysis
CEO, Steve Gourlay, provides a quick explanation of the upcoming interim analysis, due next week, and how it adds value by de-risking the trial from a safety perspective as well as ensuring that efficacy is headed sufficiently in the right direction.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Actinogen. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Actinogen a question about this update.